Starting April 21, you’ll be asked to log in or sign up for a free account after viewing 10 content pages each month.
Don’t worry—creating an account is quick and easy, and it comes with added benefits! Once logged in, you’ll not only continue accessing the content you already enjoy, but you’ll also unlock exclusive features like interactive donut plots for variant protein effects and variant impacts across the gene.
Stay tuned for these updates, and thank you for being part of our community!
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | NUV-422 |
Synonyms | |
Therapy Description |
NUV-422 inhibits CDK2/4/6, which may lead to cell cycle arrest and growth inhibition (NCI Thesaurus). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
NUV-422 | NUV422 | CDK2 Inhibitor 31 CDK4 Inhibitor 17 CDK6 Inhibitor 6 | NUV-422 inhibits CDK2/4/6, which may lead to cell cycle arrest and growth inhibition (NCI Thesaurus). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04541225 | Phase Ib/II | NUV-422 | Study of NUV-422 in Adults With Recurrent or Refractory High-grade Gliomas | Terminated | USA | 0 |
NCT05191004 | Phase Ib/II | NUV-422 Fulvestrant + NUV-422 Fulvestrant | Study of NUV-422 in Combination With Fulvestrant in Patients With HR+HER2- aBC | Withdrawn | USA | 0 |